Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06762925

Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment

This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Bladder Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Kidney Cancer Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Site Prostate Cancer Prostatic Diseases Prostatic Neoplasms Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with urinary system tumors through pathological examination;
  • Meet specific clinical stages and surgical treatment standards;
  • Intraoperative tissue resection meets the sample testing standards;
  • The patient is willing to participate in the study and sign an informed consent form.

Exclusion criteria

  • Not meeting the specific clinical stage and not receiving surgical treatment;
  • Abnormal mental behavior;
  • Intellectual disability;
  • Age under 18 years old or over 75 years old;
  • Low understanding and communication skills.

Treatment and study plan

No interventions

Other

No Interventions

Primary outcomes

  1. The expression levels of METTL3 and ANGPTL2

    Time frame: About a year and a half

Study contacts

Contact information is provided by the study sponsor or research team.

shihao shang

CONTACT

[email protected]

17868780610

Sponsors and collaborators

Lead sponsor

Xijing Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 8, 2025
Registry last updated
Jan 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.